(Q39574212)

13 September 2017

title

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy (English)

1 reference

13 September 2017

1 reference

neoadjuvant chemotherapy

1 reference

Jiayu Wang

1

1 reference

13 September 2017

Binghe Xu

2

1 reference

13 September 2017

Peng Yuan

3

1 reference

13 September 2017

Pin Zhang

4

1 reference

13 September 2017

Qing Li

5

1 reference

13 September 2017

Fei Ma

6

1 reference

13 September 2017

Ying Fan

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

3 August 2012

1 reference

Breast Cancer Research and Treatment

13 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

13 September 2017

volume

135

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

531-537

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2167-5

13 September 2017

exact match

0 references

cites work

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

HER2/neu in systemic therapy for women with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Multifactorial approach to predicting resistance to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2167-5

10.1007/S10549-012-2167-5

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference